Late-stage Pipeline and Portfolio Tripled in Size Through Clinical Trial Progress and Business Development Deals Over the Past Year
Eight Potential Approvals Across Cardiovascular Portfolio by 2030, Including Multiple Initial Launches Between 2024-28
Overall Peak Commercial Revenue Opportunity for Portfolio, Including Initial and Future Indications, Expected to Exceed $10 Billion Approaching the Mid-2030s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.